Gyre Therapeutics Stock Current Valuation
| GYRE Stock | 11.29 0.46 3.91% |
Valuation analysis of Gyre Therapeutics helps investors to measure Gyre Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 2.2 B, whereas Enterprise Value Over EBITDA is forecasted to decline to 71.65. Fundamental drivers impacting Gyre Therapeutics' valuation include:
Price Book 15.3363 | Enterprise Value 945.6 M | Enterprise Value Ebitda 80.1251 | Price Sales 8.6832 | Enterprise Value Revenue 9.0032 |
Overvalued
Today
Please note that Gyre Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Gyre Therapeutics is based on 3 months time horizon. Increasing Gyre Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Gyre stock is determined by what a typical buyer is willing to pay for full or partial control of Gyre Therapeutics. Since Gyre Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gyre Stock. However, Gyre Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.29 | Real 10.64 | Hype 11.29 | Naive 9.63 |
The real value of Gyre Stock, also known as its intrinsic value, is the underlying worth of Gyre Therapeutics Company, which is reflected in its stock price. It is based on Gyre Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Gyre Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Gyre Therapeutics helps investors to forecast how Gyre stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gyre Therapeutics more accurately as focusing exclusively on Gyre Therapeutics' fundamentals will not take into account other important factors: Gyre Therapeutics Company Current Valuation Analysis
Gyre Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Gyre Therapeutics Current Valuation | 945.64 M |
Most of Gyre Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gyre Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gyre Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Gyre Therapeutics is extremely important. It helps to project a fair market value of Gyre Stock properly, considering its historical fundamentals such as Current Valuation. Since Gyre Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gyre Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gyre Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Gyre Current Valuation Historical Pattern
Today, most investors in Gyre Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Gyre Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Gyre Therapeutics current valuation as a starting point in their analysis.
Gyre Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Gyre Therapeutics has a Current Valuation of 945.64 M. This is 93.42% lower than that of the Biotechnology sector and 79.64% lower than that of the Health Care industry. The current valuation for all United States stocks is 94.31% higher than that of the company.
Gyre Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gyre Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gyre Therapeutics could also be used in its relative valuation, which is a method of valuing Gyre Therapeutics by comparing valuation metrics of similar companies.Gyre Therapeutics is currently under evaluation in current valuation category among its peers.
Gyre Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Gyre Therapeutics from analyzing Gyre Therapeutics' financial statements. These drivers represent accounts that assess Gyre Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Gyre Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.2B | 1.8B | 418.2M | 610.1M | 1.6B | 2.3B | |
| Enterprise Value | 1.2B | 1.8B | 376.3M | 588.4M | 1.5B | 2.2B |
Gyre Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Gyre Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gyre Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Gyre Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 945.64 M | ||||
| Shares Outstanding | 85.82 M | ||||
| Shares Owned By Insiders | 74.70 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 376.58 K | ||||
| Price To Book | 15.34 X | ||||
| Price To Sales | 8.68 X | ||||
| Revenue | 113.45 M | ||||
| EBITDA | 20.33 M | ||||
| Net Income | (85.48 M) | ||||
| Total Debt | 409 K | ||||
| Book Value Per Share | (0.21) X | ||||
| Cash Flow From Operations | 25.89 M | ||||
| Short Ratio | 11.66 X | ||||
| Earnings Per Share | (1.04) X | ||||
| Number Of Employees | 593 | ||||
| Market Capitalization | 968.93 M | ||||
| Total Asset | 116.54 M | ||||
| Retained Earnings | (85.54 M) | ||||
| Working Capital | 37.17 M | ||||
| Net Asset | 116.54 M |
About Gyre Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gyre Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:Check out Gyre Therapeutics Piotroski F Score and Gyre Therapeutics Altman Z Score analysis. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.04) | Revenue Per Share 1.464 | Quarterly Revenue Growth (0.14) | Return On Assets 0.1018 |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.